Dysregulated integrin αVβ3 and CD47 signaling promotes joint inflammation, cartilage breakdown, and progression of osteoarthritis.

Autor: Wang Q; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Onuma K; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Liu C; Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, Department of Radiology and Bio-X Program, Stanford University School of Medicine, Stanford, California, USA., Wong H; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Bloom MS; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Elliott EE; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Cao RR; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Hu N; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Lingampalli N; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Sharpe O; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Zhao X; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Sohn DH; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.; Department of Microbiology and Immunology, Pusan National University School of Medicine, Yangsan, Gyeongsangnam-do, South Korea., Lepus CM; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Sokolove J; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Mao R; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Cisar CT; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Raghu H; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA., Chu CR; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.; Department of Orthopedic Surgery., Giori NJ; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.; Department of Orthopedic Surgery., Willingham SB; Institute for Stem Cell Biology and Regenerative Medicine and the Ludwig Cancer Center, and.; Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, California, USA., Prohaska SS; Institute for Stem Cell Biology and Regenerative Medicine and the Ludwig Cancer Center, and.; Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, California, USA., Cheng Z; Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, Department of Radiology and Bio-X Program, Stanford University School of Medicine, Stanford, California, USA., Weissman IL; Institute for Stem Cell Biology and Regenerative Medicine and the Ludwig Cancer Center, and.; Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, California, USA., Robinson WH; Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.

Publikováno v: JCI insight [JCI Insight] 2019 Sep 19; Vol. 4 (18). Date of Electronic Publication: 2019 Sep 19.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

Autor: Sikic BI; 1 Stanford University School of Medicine, Stanford, CA., Lakhani N; 2 South Texas Accelerated Therapeutics Midwest, Grand Rapids, MI., Patnaik A; 3 South Texas Accelerated Therapeutics, San Antonio, TX., Shah SA; 1 Stanford University School of Medicine, Stanford, CA., Chandana SR; 2 South Texas Accelerated Therapeutics Midwest, Grand Rapids, MI., Rasco D; 3 South Texas Accelerated Therapeutics, San Antonio, TX., Colevas AD; 1 Stanford University School of Medicine, Stanford, CA., O'Rourke T; 2 South Texas Accelerated Therapeutics Midwest, Grand Rapids, MI., Narayanan S; 1 Stanford University School of Medicine, Stanford, CA., Papadopoulos K; 3 South Texas Accelerated Therapeutics, San Antonio, TX., Fisher GA; 1 Stanford University School of Medicine, Stanford, CA., Villalobos V; 4 University of Colorado Cancer Center, Aurora, CO., Prohaska SS; 1 Stanford University School of Medicine, Stanford, CA., Howard M; 1 Stanford University School of Medicine, Stanford, CA., Beeram M; 3 South Texas Accelerated Therapeutics, San Antonio, TX., Chao MP; 5 Forty Seven, Menlo Park, CA., Agoram B; 5 Forty Seven, Menlo Park, CA., Chen JY; 5 Forty Seven, Menlo Park, CA., Huang J; 5 Forty Seven, Menlo Park, CA., Axt M; 5 Forty Seven, Menlo Park, CA., Liu J; 5 Forty Seven, Menlo Park, CA., Volkmer JP; 5 Forty Seven, Menlo Park, CA., Majeti R; 1 Stanford University School of Medicine, Stanford, CA.; 5 Forty Seven, Menlo Park, CA., Weissman IL; 1 Stanford University School of Medicine, Stanford, CA., Takimoto CH; 5 Forty Seven, Menlo Park, CA., Supan D; 1 Stanford University School of Medicine, Stanford, CA., Wakelee HA; 1 Stanford University School of Medicine, Stanford, CA., Aoki R; 1 Stanford University School of Medicine, Stanford, CA., Pegram MD; 1 Stanford University School of Medicine, Stanford, CA., Padda SK; 1 Stanford University School of Medicine, Stanford, CA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2019 Apr 20; Vol. 37 (12), pp. 946-953. Date of Electronic Publication: 2019 Feb 27.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Mitochondria in Cancer Stem Cells: From an Innocent Bystander to a Central Player in Therapy Resistance.

Autor: Garimella, Sireesha V (AUTHOR), Gampa, Siri Chandana (AUTHOR), Chaturvedi, Pankaj (AUTHOR)

Publikováno v: Stem Cells & Cloning: Advances & Applications. Aug2023, Vol. 16, p19-41. 23p.